Business Wire

Lineage Opens New Fully Automated Cool Port II High-Rise Cold Storage Facility in the Port of Rotterdam

23.11.2022 17:30:00 EET | Business Wire | Press release

Share

Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today officially opened its fully-automated Cool Port II cold storage facility in the Port of Rotterdam, Netherlands, adding a key European port location to Lineage’s global network of best-in-class cold storage facilities.

The fully automated deep-freeze high bay warehouse offers 60,000 pallet locations, three automated truck unloading systems and a full range of services to safely store food products and bring them to market. Strategically located in Europe’s largest sea port, the new Cool Port II facility co-located next to Cool Port I gives customers the option of tri-modal connections by sea, rail and road, connecting Lineage’s growing network from Europe to the UK and far beyond.

The facility features the industry’s most advanced automation solutions, helping to address labour volatility, provide fast and efficient service to clients and reduce the site’s energy consumption, all while ensuring the highest level of food safety and reduction of food waste. Cool Port II utilises data-driven solutions to optimise its energy use, with precision cooling cycles to minimise energy leakage and a high-rise design that maximises storage density and reduces the site’s energy footprint. Best-in-class refrigeration technology and the latest systems for temperature control combined with the energy-saving design of the facility make Cool Port II a frontrunner in energy efficiency in the cold storage sector. The site is up to 45% more energy efficient than a conventional cold storage facility.

“Our new Cool Port II facility highlights the best-in-class approach that makes Lineage a unique and forward-looking partner for our customers,” said Harld Peters, President of Europe at Lineage. “In addition to its strategic location, Cool Port II utilises the latest in automation technology. Our aim is to be a driving force behind greening the supply chain, investing in our people and our facilities to deploy the very latest in cold storage technology. In this way, we can reduce our energy footprint while providing the solutions our customers need to deliver food safely and efficiently throughout Europe and beyond.”

In addition to the increased energy efficiency of a fully automated facility, the building is constructed to meet the highest BREEAM sustainability standards. Cool Port has over 11,000 solar panels on its roof making Lineage one of the leading companies in the Port of Rotterdam when it comes to generating solar power for in-house use. As a Climate Pledge signatory, Lineage is committed to achieving net-zero carbon emissions across its operations by 2040.

“We are proud to open this state-of-the-art facility, a multi-modal facility that is well connected by road, rail and barges and the only cold store facility in Rotterdam connected with the Short Sea Terminals. We aim to provide Lineage’s customers easy access to a strong and growing network to deliver their product safely and efficiently,” said Mark Ketelaar, Regional Vice President for the Benelux Region at Lineage Logistics. “Cool Port II offers a complete range of services and state-of-the-art facilities to maximise efficiency and safe handling of the products in our care.”

In recent years Lineage has expanded its network across Europe, creating a one-stop-shop solution for customers across the continent. This reduces the complexity of moving food between countries, reduces food waste and makes the distribution of food more efficient and resilient.

About Lineage Logistics

Lineage Logistics is one of the world’s leading temperature-controlled industrial REIT and logistics solutions provider. It has a global network of over 400 strategically located facilities totalling over 2 billion cubic feet of capacity, which spans 20 countries across North America, Europe and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivalled real estate network and the development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste and, most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. Lineage is a 2022 U.S. Best Managed Company, a recognition by Deloitte Private and The Wall Street Journal for private companies that demonstrate excellence in strategic planning and execution, corporate culture and financial results. (www.lineagelogistics.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lineage Logistics
Magnus Franklin
+32471620575
magnus.franklin@teneo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye